Abbott Laboratories has developed a new software package (Abbottbase pharmacokinetic system or PKS package) that employs the principles of pharmacokinetics to assist clinical pharmacologists and clinicians in designing dosage regimens. This software, which runs on IBM PC compatibles, allows Bayesian estimation of individual pharmacokinetic parameters. The aim of the present study was to validate this new system in routine clinical practice for amikacin (40 intensive care unit patients) and theophylline (20 patients). By using the program one or more times during the treatment (50 cases for amikacin and 46 cases for theophylline), dosing recommendations were obtained in real time for all patients. The predictive performance (bias and precision) was assessed by comparing predicted drug concentrations with those measured 24-48 h after dosage recommendation. In the case of amikacin, precision and bias were computed separately for peak and trough levels. In all cases, no statistically significant bias was observed. Finally, our results demonstrate the accuracy of the program in predicting drug levels for amikacin and theophylline. Consequently, the PKS package is reliable for the choice of optimal dosage regimen for amikacin and theophylline.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0020-7101(94)90103-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Global, regional, and national trends in drug use disorder mortality rates across 73 countries from 1990 to 2021, with projections up to 2040: a global time-series analysis and modelling study.
EClinicalMedicine
January 2025
Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.
Background: Drug use disorder (DUD) poses a major public health crisis globally, necessitating immediate attention to global trends and future projections to develop effective health policies and interventions. Thus, we aimed to estimate the global trends in DUD mortality rates from 1990 to 2021 and future projections of DUD deaths until 2040 across 73 countries.
Methods: In this time-series analysis and modelling study, we investigated the global trends in DUD mortality rates from 1990 to 2021 using the WHO Mortality Database and forecasted future trends through 2040.
Genetic analysis of L 1758 (Mollusca, Bivalvia, Pinnidae) in the Northwest Cabo Verde Islands (Central-East Atlantic).
PeerJ
January 2025
CIBIO, Centro de Investigação em Biodiversidade e Recursos Genéticos, InBIO Laboratório Associado, Universidade do Porto, Campus de Vairão, Porto, Portugal.
The rough pen shell Linnaeus, 1758 (family Pinnidae) is a mollusc with an Atlantic-Mediterranean distribution, typically inhabiting coarse sandy substrates. Habitat degradation is considered the primary cause of population decline, leading to the designation 'Vulnerable' in certain regions. In this study, we conducted a genetic analysis of populations of from Cabo Verde and compared them with populations from the Mediterranean and Macaronesia.
View Article and Find Full Text PDFNetwork characteristics of comorbid symptoms in alcohol use disorder.
Ann Med
December 2025
School of Special Education and Rehabilitation, BinZhou Medical University, Yantai, China.
Background: Individuals with alcohol use disorder (AUD) often experience symptoms such as anxiety, depression, and decreased sleep quality. Although these are not diagnostic criteria, they may increase dependence risk and complicate treatment. This study aims to analyze comorbidities and their complex relationships in AUD patients through epidemiological surveys and network analysis.
View Article and Find Full Text PDFUnveiling the safety profile of lecanemab: A comprehensive analysis of adverse events using FDA adverse event reporting system data.
J Alzheimers Dis
January 2025
Department of Pharmacy, Women and Children's Hospital of Ningbo University, Ningbo, China.
Background: Lecanemab, a novel monoclonal antibody targeting amyloid-β, has shown promise in treating Alzheimer's disease. Comprehensive post-marketing safety data analysis is crucial to understand its real-world risk profile.
Objective: This study aimed to evaluate the safety profile of lecanemab using data from the FDA Adverse Event Reporting System (FAERS), with a focus on nervous system disorders and amyloid-related imaging abnormalities.
Causal inference with cross-temporal design.
Biometrics
January 2025
Department of Biostatistics, Brown University, Providence, RI 02903, United States.
When many participants in a randomized trial do not comply with their assigned intervention, the randomized encouragement design is a possible solution. In this design, the causal effects of the intervention can be estimated among participants who would have experienced the intervention if encouraged. For many policy interventions, encouragements cannot be randomized and investigators need to rely on observational data.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!